Abiomed's heart pump gets EU nod

Thu Apr 12, 2012 6:30pm IST

A zoomed picture shows two surgeons performing an operation to implant an artificial heart valve in the operating room of a Berlin hospital August 15, 2003. REUTERS/Fabrizio Bensch

A zoomed picture shows two surgeons performing an operation to implant an artificial heart valve in the operating room of a Berlin hospital August 15, 2003.

Credit: Reuters/Fabrizio Bensch

Related Topics

Stocks

   

(Reuters) - Abiomed Inc said European health regulators approved the use of its heart pump in cardiac surgery.

The Danvers, Massachusetts-based company said the device, called Impella cVAD, is expected to be commercially available in Europe by this summer.

The device is intended for use in cardiac surgery for supporting the weakened heart's left ventricle, which is responsible for pumping oxygen-rich blood from the lungs throughout the body.

Impella cVAD is still not approved in the United States.

Abiomed shares closed at $20.90 on Wednesday on the Nasdaq.

(Reporting by Anand Basu in Bangalore; Editing by Viraj Nair)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

Disease Outbreak

REUTERS SHOWCASE

Reading the Brain

Reading the Brain

Guilt may spoil restorative effects of entertainment.  Full Article 

Heart Matters

Heart Matters

Weekday heart attacks still getting quicker treatment at hospitals.  Full Article 

Tackling Stress

Tackling Stress

'Interreality' may enhance stress therapies.  Full Article 

Jogging Helps

Jogging Helps

Short jogs linked to lower risk of death from heart disease.  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage